ElsaLys Biotech SA

AbbVie Inc. has returned its rights to a MerTK inhibitor program licensed from originator Dong-A ST well over four years ago, marking a setback for the leading South Korean pharma firm’s plan to step

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Roche Pays Vividion $135m Up Front In

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in